Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
NCT ID: NCT03664843
Last Updated: 2018-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2018-11-09
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).
NCT03634826
Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer
NCT02645318
Multiplex Analysis of Circulating Tumor DNA
NCT03301961
ctDNA as a Biomarker for Treatment in Advanced NSCLC
NCT05486988
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
NCT02696525
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The chemotherapy cohort
Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
No interventions assigned to this group
The radiotherapy cohort
Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
No interventions assigned to this group
The targeted therapy cohort
Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with stage III-IV NSCLC;
3. Have the tissue specimens (fresh or wax blocks) before this treatment;
4. PS\<=2 in radiotherapy/ chemotherapy group; PS\<=3 in targeted therapy group
5. Signing informed consent;
Exclusion Criteria
2. Incorporating any unstable systemic disease;
3. Histology is not NSCLC;
4. Unqualified blood samples;
5. Patients lacking any one of the detection points.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Affiliated Hospital of Hebei University
OTHER
Hebei Medical University Fourth Hospital
OTHER
Xingtai People's Hospital
OTHER
First Hospital of Shijiazhuang City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Zhang, M.D.
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Shijiazhuang
Jun Wang, M.D.
Role: STUDY_CHAIR
Peking University People's Hospital
Kezhong Chen, M.D.
Role: STUDY_DIRECTOR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Hebei Medical University Fourth Hospital
Shijiazhuang, Hebei, China
The First Hospital of Shijiazhuang
Shijiazhuang, Hebei, China
Xingtai People's Hospital
Xingtai, Hebei, China
Handan Downtown Hospital
Handan, Heibe, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yanhong Shang
Role: primary
Wenbin Shen
Role: primary
Xiaozhen Wang
Role: primary
Yuquan Ma
Role: primary
Dingzhi Huang, M.D.
Role: primary
Jun Chen, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTH01801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.